Every Form 4 that EVOGENE LTD. (EVGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EVGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVGN filings page.
Evogene Ltd. (EVGN) granted director Leon Recanati 2,500 stock options on September 4, 2026, with an exercise price of $0.58 per ordinary share. The options were granted under Evogene's 2021 Share Incentive Plan and vest quarterly at 25% per quarter beginning September 4, 2026, becoming fully vested September 4, 2027. They expire September 4, 2036. A separate informational holding entry lists 1,343,886 ordinary shares held directly.
Evogene Ltd. director Nir Nimrodi received 10,000 stock options on September 4, 2026, under the company’s 2021 Share Incentive Plan. The options have an exercise price of NIS 1.75 per share, equivalent to $0.58 per share, vest 25% per quarter beginning on the grant date, become fully vested by September 4, 2027, and expire September 4, 2036.
The filing also lists existing direct options covering 5,625 ordinary shares at an $11.00 exercise price, expiring April 20, 2030; 1,800 shares each at $10.20, $6.40 and $6.60, expiring September 15, 2032, May 11, 2033 and June 15, 2034; and 10,000 shares at $1.29, expiring August 18, 2035.
Evogene Ltd. (EVGN) director Adrian John Percy received a grant of 2,500 stock options on September 4, 2026, under the 2021 Share Incentive Plan. The options have a $0.58-per-share exercise price and vest 25% per quarter beginning on the grant date, becoming fully vested by September 4, 2027; they expire September 4, 2036. Separately, reported direct options include 1,000 underlying shares at $25.60, expiring December 23, 2028, and 2,500 at $1.29, expiring August 18, 2035.
Evogene Ltd. reported that director Dan Michael Falk received a grant of 2,500 stock options on September 4, 2026, under the company's 2021 Share Incentive Plan. The options cover 2,500 ordinary shares and have an exercise price of $0.58 per share.
The options vest quarterly at 25% per quarter beginning September 4, 2026, and become fully vested by September 4, 2027. The report also lists four direct option holdings: 1,800 underlying shares at $10.51, expiring September 15, 2032; 1,800 at $6.03, expiring May 11, 2033; 1,800 at $7.16, expiring June 13, 2034; and 2,500 at $1.29, expiring August 18, 2035.
Evogene Ltd. (EVGN) reported that Chief Development Officer Tarcic Gabi purchased 1,129 Ordinary Shares on June 4, 2026 at $0.60 per share in an open-market or private transaction. Following this buy, Tarcic holds 1,129 Ordinary Shares directly and has stock options covering 40,000 Ordinary Shares at an exercise price of $2.305 per share, expiring November 20, 2034. The option position was unchanged and is disclosed for informational purposes, with vesting over four years from the November 20, 2024 grant date.
Evogene Ltd. director Leon Recanati reported purchasing 460,000 Ordinary Shares on August 11, 2026 at $0.635 per share in an open-market or private transaction. Following this trade, he directly holds 1,343,886 Ordinary Shares. The filing also lists several existing stock option awards over Ordinary Shares at exercise prices ranging from $1.29 to $54.32 with expirations between 2027 and 2035; per the footnotes, these option rows reflect holdings only and no new transactions.
Evogene Ltd. director Leon Recanati purchased 800,000 Ordinary Shares on August 4, 2026 in multiple transactions at a weighted average price of $0.50 per share, increasing his direct ownership to 883,886 Ordinary Shares. He also reports existing stock option positions for informational purposes.